查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853643

生技藥品契約製造市場按分子類型、製程步驟、生產規模、技術平台、治療領域、最終用戶和生產模式分類－2025-2032年全球預測

Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生技藥品契約製造市場規模將達到 950 億美元，複合年成長率為 17.28%。

關鍵市場統計數據
基準年 2024 265.3億美元
預計年份：2025年 310.4億美元
預測年份 2032 950億美元
複合年成長率 (%) 17.28%

本文簡要概述了科學突破和商業需求如何重塑生技藥品契約製造策略和執行。

生技藥品契約製造產業融合了科學創新、嚴格的監管要求和工業規模生產。過去十年，細胞和基因治療、單株抗體、重組蛋白和疫苗研發的進步改變了人們對速度、靈活性和產品特定製程設計的期望。因此，契約製造生產商必須在確保不同客戶專案品質一致並符合監管要求的同時，兼顧複雜的科學工作流程和產業限制。

更具體地說，企業日益面臨著提供從上游研發到灌裝、包裝和分析測試的端到端服務的需求，同時還要應對從臨床前測試到全面商業化生產的各種生產規模。這種不斷變化的需求凸顯了模組化設施設計和跨職能計劃管理能力的重要性。此外，在選擇一次性系統或傳統不銹鋼平台時，必須根據長期營運成本、污染風險和宣傳活動彈性進行策略評估。

因此，那些將技術專長、敏捷的供應鏈管理和清晰的監管策略相結合的公司將獲得決定性優勢。本報告檢驗了這些動態，並為高管提供了必要的背景資訊，以便他們將投資、夥伴關係和產能規劃與定義生技藥品成功生產的科學和商業性現實相協調。

技術進步、治療方法多樣化和供應鏈演變如何改變生技藥品的生產實踐和夥伴關係模式

生技藥品契約製造格局正在經歷一場變革，其驅動力包括技術成熟、治療產品線的變化以及供應鏈中風險認知的轉變。細胞和基因療法等先進治療方法正在引入高度個人化的產品形式，這需要客製化的製程開發、封閉式系統操作和嚴格的低溫運輸物流。同時，單株抗體和重組蛋白仍需要高通量、穩健的生產平台，並專注於產量最佳化和下游純度。

向一次性技術的轉變正在加速多宣傳活動設施的靈活性，縮短週轉時間，同時採購重點也轉向經過檢驗的供應商，確保一次性組件的穩定供應。同時，注射用生技藥品和組合藥物最終產品完整性和包裝的複雜性日益增加，使得填充和包裝操作更加重要。監管體係也不斷調整，對可比較性、病毒安全性和資料完整性的審查力度加大，提高了分析檢測能力的要求。

因此，製造模式日益碎片化：一些贊助商傾向於使用專用設施以實現策略控制，而另一些則選擇按服務收費或虛擬製造來節省資金並加快研發速度。這種累積效應迫使契約製造製造商透過提供基於平台的解決方案、投資於可適應性強的工藝流程以及加強與整個價值鏈的夥伴關係來保持競爭力並增強韌性。

評估美國關稅調整對生技藥品生產投入和策略採購決策的營運和供應鏈影響

預計2025年將推出的關稅調整和貿易政策變化迫使企業重新評估籌資策略、供應商選擇以及生產和採購的地理分佈。進口一次性零件、特殊不銹鋼配件和生物加工耗材的關稅增加，可能會推高投入成本並擠壓利潤空間，除非製造商和贊助商採取補償措施。

為此，許多公司正在加快供應商資格認證流程，拓展合格供應商名單，並探索近岸外包和回流生產方案，以減輕跨境關稅的影響。這種轉變正促使資金流入區域供應鏈和國內製造能力，尤其是高價值或關鍵型投入品。此外，採購團隊也在重新談判長期契約，並儘可能製定對沖策略，以穩定成本走勢。

因此，關稅壓力也會影響新設施的位置決策，促使企業投資於可減少對高關稅進口產品依賴的替代技術，並加強專案發起人和契約製造之間的合作，以共用風險。雖然關稅會帶來一些不利影響，但它們也能推動本地韌性的提升、供應商的發展以及策略性合約結構的構建，從而保障專案進度和產品品質。

詳細的細分分析揭示了分子類型、製程步驟、生產規模、技術平台、治療領域、最終用戶和生產模式如何驅動產能需求。

一個完善的細分框架能夠明確哪些方面需要提升能力以滿足客戶需求，以及哪些方面的投資能帶來最大的營運回報。從細胞療法、基因療法、單株抗體、重組蛋白和疫苗等分子類型的角度進行細分，可以發現製程要求有顯著差異。細胞和基因平台需要封閉式系統和專門的病毒載體處理流程，而單株抗體則更專注於高效價上游工程和精細的下游純化。

同樣，將價值鏈按製程步驟（分析測試、下游、填充、配方和上游）分解，可以發現不同的技能組合、設備配置和監管要求，這些都必須在整個計劃週期中進行協調。將生產規模從臨床前研究分解為 I 期、II 期、III 期和商業化階段，會帶來節奏和生產力計畫的挑戰，因為不同平台技術和分子類別的放大路徑差異顯著。

技術平台的選擇——一次性系統與不銹鋼系統——也會影響設施佈局、轉換時間和驗證策略。自體免疫、感染疾病、腫瘤和罕見疾病等治療領域具有不同的風險接受度和計畫進度，這會影響優先排序。生物技術公司、合約服務供應商、製藥公司和研究機構等最終用戶需要根據自身需求量身定做的合約模式和服務等級協議。最後，生產模式（專用設施、按服務收費、多產品設施、虛擬生產）決定了資本密集度、利潤結構和商業性彈性。這些細分視角為能力藍圖提供訊息，並幫助高階主管確定投資優先級，從而使營運設計與客戶需求保持一致。

區域動態及其對全球市場產能分配、監管影響和跨境製造夥伴關係的策略意義

區域動態持續影響受託製造製造商和申辦者的策略重點，他們需要評估產能分配和監管互動。在美洲，強大的生物技術生態系統和完善的法律規範支持著模組化生產能力的快速臨床應用和私人投資，而該地區成熟的供應鏈則為研發階段和商業化生產的穩健外包夥伴關係提供了保障。

相較之下，歐洲、中東和非洲呈現出異質性格局，高監管標準與各國對生物製造投資的不同獎勵並存，而在中東和非洲的部分地區，區域政策舉措旨在透過有針對性的激勵措施和官民合作關係來激活當地能力。

亞太地區已成為產能擴張的中心，這得益於其大規模製藥生產經驗、蓬勃發展的國內生物技術產業以及政府為保障生產自主權而採取的支持性舉措。儘管跨國合作在該地區依然可行，但決策者在位置和供應商合格方面，越來越重視地緣政治風險、貿易政策和區域物流韌性等因素。這些區域差異會影響企業進行研發活動的地點、合作夥伴的選擇以及如何建立其全球生產網路，以平衡速度、成本和監管准入。

供應商如何透過技術專長、整合分析、策略合作夥伴關係和靈活的製造地來滿足不同贊助商的需求，從而脫穎而出

領先的契約製造製造商和服務供應商正透過平台專業化、整合服務以及拓展技術深度和地理覆蓋範圍的投資來提升自身競爭力。一些公司專注於先進的治療能力，例如病毒載體生產和封閉式細胞療法工藝，而另一些公司則致力於擴大抗體和重組蛋白的生產規模，以支持大規模商業項目。在整個產業中，分析檢測能力已成為一項重要的競爭優勢，各公司紛紛增加高通量表徵、效力測定和先進的生物分析技術，以縮短產品上市週期並支援複雜的可比性分析方案。

合作模式多種多樣：與元件供應商建立策略聯盟可確保一次性材料的持續供應，而與區域性企業成立合資企業則有助於快速進入市場並實現本地化供應。採用彈性製造系統並投資自動化技術的公司能夠提高宣傳活動效率和資料完整性，而那些優先考慮監管溝通和品質系統的公司則能降低核准風險並加速技術轉移。最終，競爭優勢源於將卓越的技術能力與服務編配相結合的能力，從而使客戶能夠順利地將專案從早期研發階段推進到商業化供應階段，避免分散和不必要的延誤。

為增強韌性、最佳化營運以及使生產能力藍圖與新興的治療方法和監管需求保持一致，提出切實可行的建議。

產業領導者應採取果斷行動，增強韌性，提高成本效益，並從不斷變化的治療趨勢中獲取價值。首先，企業應優先考慮設施設計的模組化，並檢驗一次性製程和不銹鋼製程的互通性，以保持宣傳活動的靈活性並縮短換線時間。同時，投資強大的分析測試平台和可擴展的下游生產能力，可以簡化可比性論證流程，並縮短複雜生技藥品的上市時間。

其次，企業應實現關鍵消耗品和原料供應商組合的多元化，盡可能採取區域籌資策略，以加快供應商資格確認並降低關稅和貿易風險。此外，營運負責人應制定正式的技術藍圖，包括增強自動化、數位化批次記錄和流程分析技術，以提高可重複性和合應對力。第三，企業應評估混合製造模式，將策略專案的專用產能與高混合度和按服務收費的選項結合，以在確保客戶機密性的同時最佳化產能利用率。

最後，加強與贊助商、學術中心和當地相關人員的夥伴關係，可以加快人才隊伍建設，並促進與監管機構的互動。落實這些建議，將使我們能夠應對治療方法創新、政策變化和供應鏈波動，同時維持產品品質和專案連續性的高標準。

透過結合從業者訪談、監管分析、採購模式和技術文獻的透明三角測量調查方法，獲得可操作的見解。

本分析整合了來自行業訪談、技術白皮書、監管指南更新和已發布的策略文件的定性和定量資訊。此分析方法強調三角驗證。來自高階營運、品質和商業領導者的關鍵見解與技術文獻和產品平臺揭露資訊進行交叉比對，檢驗營運影響和新興趨勢。此外，還檢視了設備採購模式、專利活動和已報告的產能擴張情況，以推斷平台採用和區域擴張的變化。

透過檢驗監管通知和測試結果，數據完整性得到提升，這突顯了合規方面的重點關注領域，並加快了對病毒安全性、無菌保證和分析廣度方面關鍵能力差距的識別。在適當情況下，使用了近期技術轉移中的匿名案例研究，以說明實際的限制因素和成功的緩解策略。雖然本文討論中未包含專有的定量預測，但調查方法透過記錄資訊來源、訪談通訊協定以及用於評估技術和供應商的標準，確保了透明度。

總體而言，這種方法將實踐者的經驗與有據可查的證據相結合，為生技藥品契約製造領域的管理人員在資本、採購和夥伴關係決策方面提供可操作且有理有據的見解。

總結關於產能投資、供應鏈韌性和夥伴關係模式調整以確保複雜生物製藥可靠供應的觀點

生技藥品契約製造產業正處於一個關鍵時刻，科學創新與營運策略必須融合才能確保專案成功。對單株抗體和重組蛋白的持續需求，以及細胞和基因療法的進步，都對製造商提出了技術深度和營運靈活性的雙重要求。供應鏈壓力和政策變化凸顯了多元化採購和區域韌性的重要性，而一次性系統和不銹鋼系統之間的技術選擇則需要與專案風險狀況和產能需求進行仔細匹配。

整合強大的分析能力、模組化設施設計和策略供應商關係的管理者，將更有能力將創新與可靠的供應連結起來。此外，採用靈活的商業模式，平衡專用產能和多樣化產品，將使他們能夠在不犧牲品質或速度的前提下滿足多樣化的客戶需求。隨著行業的不斷發展，領導者必須使投資重點與治療趨勢和監管預期保持一致，以保持競爭力並確保患者能夠獲得複雜的生物製藥。

這意味著，要取得進展，需要精心設計能力、積極主動地進行風險管理，以及建立合作夥伴關係，以提供開發和商業化現代生技藥品所需的營運可靠性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 提高生技藥品生產效率，越來越多採用連續生產平台
  • 營運成本降低和專業技能提升推動亞洲契約製造組織的擴張
  • 一次性生物反應器技術的整合降低了交叉污染的風險和停機時間。
  • 擴大外包夥伴關係，以加速基因和細胞療法生產的規模化發展
  • 運用先進的分析和人工智慧技術最佳化生物製藥製程產量比率並降低成本
  • 對品質合規性的監管審查日益嚴格，推動了對數位化批次記錄系統和可追溯性的投資。
  • 為滿足高細胞密度生產流程的需求，轉向中空纖維和灌注式生物反應器
  • 開發用於快速擴大多功能生物製藥生產線規模的模組化、靈活設施

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章生技藥品契約製造市場（以分子類型分類）

  • 細胞療法
  • 基因治療
  • 單株抗體
  • 重組蛋白
  • 疫苗

第9章生技藥品契約製造市場（依製程步驟分類）

  • 分析測試
  • 下游
  • 填充和精加工
  • 配方
  • 上游

第10章生技藥品契約製造市場（依生產規模分類）

  • 商業的
  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前

第11章生技藥品契約製造市場：技術平台

  • 免洗系統
  • 不銹鋼系統

第12章生技藥品契約製造市場（依治療領域分類）

  • 自體免疫
  • 感染疾病
  • 腫瘤學
  • 罕見疾病

第13章生技藥品契約製造市場（依最終用戶分類）

  • 生技公司
  • 簽約服務供應商
  • 製藥公司
  • 研究所

第14章生技藥品契約製造市場（依生產模式分類）

  • 專用設施
  • 服務費
  • 多產品工廠
  • 虛擬製造

第15章生技藥品契約製造市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章生技藥品契約製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國生技藥品契約製造市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Lonza Group Ltd.
    • Samsung Biologics Co., Ltd.
    • Catalent, Inc.
    • Wuxi Biologics（Cayman）Inc.
    • Thermo Fisher Scientific Inc.
    • Boehringer Ingelheim International GmbH
    • Fujifilm Diosynth Biotechnologies USA, Inc.
    • AGC Biologics Inc.
    • Recipharm AB
    • KBI Biopharma, Inc.
Product Code: MRR-8C74ADFBFD4E

The Biologics Contract Manufacturing Market is projected to grow by USD 95.00 billion at a CAGR of 17.28% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 26.53 billion
Estimated Year [2025] USD 31.04 billion
Forecast Year [2032] USD 95.00 billion
CAGR (%) 17.28%

A concise overview of how scientific breakthroughs and operational demands are reshaping biologics contract manufacturing strategy and execution

The biologics contract manufacturing sector operates at the confluence of scientific innovation, regulatory rigor, and industrial-scale production. Over the last decade, advances in cell and gene therapies, monoclonal antibodies, recombinant proteins, and vaccine development have shifted expectations for speed, flexibility, and product-specific process design. As a result, contract manufacturers must reconcile complex scientific workflows with industrial constraints while ensuring consistent quality and regulatory compliance across diverse customer programs.

More specifically, firms increasingly confront the need to provide integrated services that span upstream development through fill-finish and analytical testing, while accommodating varied production scales from preclinical runs to full commercial manufacture. This evolving requirement has amplified the importance of modular facility design and cross-functional project management capabilities. Moreover, technology choices between single-use systems and traditional stainless steel platforms now require strategic evaluation against long-term operational costs, contamination risk profiles, and campaign flexibility.

Consequently, companies that align technical expertise with responsive supply chain management and a clear regulatory strategy will gain a decisive advantage. This report examines those dynamics and provides the context necessary for executives to align investments, partnerships, and capacity planning with the scientific and commercial realities that define successful biologics manufacturing engagements.

How technological advances, therapeutic diversification, and supply chain evolution are jointly transforming biologics manufacturing practices and partnership models

The landscape of biologics contract manufacturing is undergoing transformative shifts driven by technological maturation, changing therapeutic pipelines, and evolving risk perceptions across supply chains. Advanced therapies such as cell and gene modalities have introduced highly personalized product formats that require bespoke process development, closed-system handling, and stringent cold-chain logistics. At the same time, monoclonal antibodies and recombinant proteins continue to demand high-throughput, robust manufacturing platforms that emphasize yield optimization and downstream purity.

Transitioning to single-use technologies has accelerated flexibility and reduced turnaround for multi-campaign facilities, yet it has also shifted procurement emphasis toward validated suppliers and disposable component supply security. In parallel, fill-finish operations have attracted renewed focus as final product integrity and packaging complexities increase with parenteral biologics and combination products. Regulatory regimes are adapting, with greater scrutiny on comparability, viral safety, and data integrity, thereby raising the bar for analytical testing capabilities.

As a result, manufacturing models are fragmenting: some sponsors favor dedicated facilities for strategic control, whereas others opt for fee-for-service or virtual manufacturing arrangements to preserve capital and speed development. The cumulative effect encourages contract manufacturers to offer platform-based solutions, invest in adaptable process trains, and strengthen partnerships across the value chain to remain competitive and resilient.

Assessing the operational and supply chain consequences of the United States tariff adjustments for biologics manufacturing inputs and strategic sourcing decisions

Anticipated tariff changes and trade policy adjustments announced for 2025 are prompting companies to reassess procurement strategies, supplier selection, and geographic distribution of manufacturing and sourcing. Tariff-driven increases on imported single-use components, specialized stainless steel fittings, and bioprocess consumables can elevate input costs and compress margins unless manufacturers and sponsors implement compensatory measures.

In response, many organizations are accelerating supplier qualification programs, diversifying approved vendor lists, and exploring nearshoring or reshoring alternatives to mitigate exposure to cross-border duties. These shifts are prompting capital deployment into regional supply chains and domestic manufacturing capacity, especially for high-value or mission-critical inputs. Additionally, procurement teams are renegotiating long-term agreements and developing hedging strategies where feasible to stabilize cost trajectories.

Consequently, tariff pressures also influence site selection decisions for new facilities, encourage investment in alternative technologies that reduce reliance on tariffed imports, and increase collaboration between sponsors and contract manufacturers to share risk. While tariffs present headwinds, they simultaneously create an impetus for localized resilience, supplier development, and strategic contract structures that protect program timelines and product quality.

Detailed segmentation analysis revealing how molecule types, process steps, production scales, technology platforms, therapeutic focuses, end users, and manufacturing models drive capability requirements

A robust segmentation framework clarifies where capabilities must align with customer needs and where investments will yield the greatest operational return. When segmentation is viewed through the lens of molecule types such as cell therapy, gene therapy, monoclonal antibody, recombinant protein, and vaccine, it becomes clear that process requirements diverge significantly: cell and gene platforms need closed systems and specialized viral vector processing, while monoclonal antibodies emphasize high-titer upstream processes and intensive downstream purification.

Similarly, dissecting the value chain by process steps-analytical testing, downstream, fill-finish, formulation, and upstream-reveals discrete skill sets, equipment footprints, and regulatory demands that must be coordinated across project timelines. Production scale segmentation from preclinical through Phase I, Phase II, Phase III, to commercial introduces cadence and capacity planning challenges, as scale-up pathways differ materially between platform technologies and molecule classes.

Technology platform choices between single-use systems and stainless steel systems also shape facility layout, changeover time, and validation strategies. Therapeutic areas such as autoimmune, infectious disease, oncology, and rare disease drive different risk tolerances and program velocities that affect prioritization. End users including biotechnology companies, contract service providers, pharmaceutical companies, and research institutes require tailored engagement models and service level agreements. Finally, manufacturing models-dedicated facility, fee-for-service, multiproduct facility, and virtual manufacturing-determine capital intensity, margin structure, and commercial flexibility. Together, these segmentation lenses inform capability roadmaps and help executives prioritize investments that align operational design with client needs.

Regional dynamics and strategic implications for capacity allocation, regulatory engagement, and cross-border manufacturing partnerships across global markets

Regional dynamics continue to shape strategic priorities for contract manufacturers and sponsors as they assess capacity allocation and regulatory engagement. In the Americas, strong biotech ecosystems and well-established regulatory frameworks favor rapid clinical translation and private investment into modular manufacturing capacity, while the region's mature supply chains support robust outsourcing partnerships for both discovery-stage work and commercial production.

In contrast, Europe, Middle East & Africa present a heterogeneous landscape where high regulatory standards coexist with varying national incentives for biomanufacturing investment. Several European markets emphasize advanced therapeutics and have strong academic-industry linkages that support translational pipelines, whereas regional policy initiatives in parts of the Middle East and Africa aim to bootstrap local capabilities through targeted incentives and public-private partnerships.

Asia-Pacific has emerged as a focal point for capacity expansion, driven by large-scale pharmaceutical manufacturing experience, growing domestic biotech sectors, and government-backed initiatives to secure manufacturing sovereignty. Across all regions, cross-border collaboration persists, but decision-makers are increasingly factoring geopolitical risk, trade policy, and regional logistics resilience into site selection and supplier qualification decisions. These regional nuances influence where companies place development activities, which partners they select, and how they sequence global production networks to balance speed, cost, and regulatory access.

How providers are differentiating through technical specialization, integrated analytics, strategic alliances, and flexible manufacturing footprints to meet diverse sponsor needs

Leading contract manufacturers and service providers are differentiating through platform specialization, integrated service offerings, and investments that expand both technical depth and geographic reach. Some firms concentrate on advanced therapy capabilities such as viral vector production and closed-system cell therapy processes, while others build scale in antibody and recombinant protein production to serve large-volume commercial programs. Across the sector, analytical testing proficiency has become a competitive differentiator, with companies adding high-throughput characterization, potency assays, and advanced bioanalytics to shorten release cycles and support complex comparability packages.

Partnership models also vary: strategic alliances with component suppliers ensure continuity of single-use materials, whereas joint ventures with regional players facilitate faster market entry and localized supply. Meanwhile, firms that adopt flexible manufacturing systems and invest in automation see improvements in campaign efficiency and data integrity, while those that prioritize regulatory engagement and quality systems reduce approval risks and accelerate tech transfers. Ultimately, competitive positioning derives from the ability to combine technical excellence with service orchestration, enabling clients to move programs from early development into commercial supply without fragmentation or unnecessary delay.

Actionable recommendations for strengthening resilience, optimizing operations, and aligning manufacturing capability roadmaps with emerging therapeutic and regulatory demands

Industry leaders should take decisive actions to strengthen resilience, improve cost-efficiency, and capture value from evolving therapeutic trends. First, organizations should prioritize modularity in facility design and validate the interoperability of single-use and stainless steel process trains to maintain campaign agility and reduce changeover time. Concurrently, investing in robust analytical testing platforms and scalable downstream capabilities will streamline comparability demonstrations and reduce release timelines for complex biologics.

Second, companies must diversify supplier portfolios for critical disposables and raw materials, accelerate supplier qualification, and pursue regional sourcing strategies where feasible to mitigate tariff and trade risks. In addition, operational leaders should formalize technology roadmaps that include increased automation, digital batch records, and process analytical technology to enhance reproducibility and regulatory readiness. Third, firms should evaluate hybrid manufacturing models that blend dedicated capacity for strategic programs with multiproduct and fee-for-service offerings to optimize utilization and preserve client confidentiality.

Finally, strengthening collaborative partnerships with sponsors, academic centers, and regional stakeholders will accelerate talent development and regulatory alignment. Implementing these recommendations will better position organizations to respond to therapeutic innovation, policy shifts, and supply chain perturbations while maintaining high standards of product quality and program continuity.

Transparent and triangulated research methodology combining practitioner interviews, regulatory analysis, procurement patterns, and technical literature to produce actionable insights

This analysis synthesizes qualitative and quantitative inputs drawn from industry interviews, technical white papers, regulatory guidance updates, and publicly reported strategic filings. The methodology emphasizes triangulation: primary insights from senior operations, quality, and commercial leaders were cross-referenced against technical literature and product pipeline disclosures to validate operational implications and emergent trends. Equipment procurement patterns, patent activity, and reported capacity expansions were examined to infer directional shifts in platform adoption and geographic deployment.

Data integrity was reinforced through validation of regulatory notifications and inspection outcomes, which helped surface areas of recurring compliance focus and accelerated the identification of critical capability gaps in viral safety, sterility assurance, and analytical breadth. Where appropriate, anonymized case studies from recent tech transfers were used to illustrate practical constraints and successful mitigation strategies. While proprietary quantitative projections were not included in this narrative, the methodology supports transparency by documenting sources, interview protocols, and criteria used for technology and supplier assessment.

Collectively, this approach balances practitioner experience with documentary evidence to produce actionable, defensible insights for executives making capital, sourcing, and partnership decisions in the biologics contract manufacturing space.

Concluding perspectives on aligning capability investment, supply chain resilience, and partnership models to reliably deliver complex biologic therapies

The biologics contract manufacturing sector stands at a pivotal moment where scientific innovation and operational strategy must converge to sustain program success. Advances in cell and gene therapies, alongside enduring demand for monoclonal antibodies and recombinant proteins, require manufacturers to be both technically deep and operationally nimble. Supply chain pressures and policy shifts highlight the importance of diversified sourcing and regional resilience, while technology choices around single-use versus stainless steel systems demand careful alignment with program risk profiles and throughput needs.

Executives who integrate robust analytical capabilities, modular facility design, and strategic supplier relationships will be better positioned to translate innovation into reliable supply. Moreover, adopting flexible commercial models that balance dedicated capacity with multiproduct offerings enables firms to serve diverse client needs without sacrificing quality or speed. As the industry evolves, leaders must synchronize investment priorities with therapeutic trends and regulatory expectations to maintain competitiveness and ensure patient access to complex biologic therapies.

In short, the path forward requires deliberate engineering of capabilities, proactive risk management, and collaborative partnerships that together deliver the operational reliability necessary for modern biologics development and commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of continuous manufacturing platforms to enhance biologic production efficiency
  • 5.2. Expansion of Asian contract manufacturing organizations driven by lower operational costs and expertise
  • 5.3. Integration of single-use bioreactor technologies to reduce cross-contamination risks and downtime
  • 5.4. Growing outsourcing partnerships to accelerate gene therapy and cell therapy manufacturing scale-up
  • 5.5. Implementation of advanced analytics and AI to optimize biologics process yields and reduce costs
  • 5.6. Increased regulatory scrutiny on quality compliance driving investment in digital batch record systems and traceability
  • 5.7. Shift towards hollow fiber and perfusion bioreactors to meet demand for high-cell density manufacturing processes
  • 5.8. Development of modular flexible facilities for rapid scale-up of multifunctional biologics production lines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Manufacturing Market, by Molecule Type

  • 8.1. Cell Therapy
  • 8.2. Gene Therapy
  • 8.3. Monoclonal Antibody
  • 8.4. Recombinant Protein
  • 8.5. Vaccine

9. Biologics Contract Manufacturing Market, by Process Step

  • 9.1. Analytical Testing
  • 9.2. Downstream
  • 9.3. Fill Finish
  • 9.4. Formulation
  • 9.5. Upstream

10. Biologics Contract Manufacturing Market, by Production Scale

  • 10.1. Commercial
  • 10.2. Phase I
  • 10.3. Phase II
  • 10.4. Phase III
  • 10.5. Preclinical

11. Biologics Contract Manufacturing Market, by Technology Platform

  • 11.1. Single Use System
  • 11.2. Stainless Steel System

12. Biologics Contract Manufacturing Market, by Therapeutic Area

  • 12.1. Autoimmune
  • 12.2. Infectious Disease
  • 12.3. Oncology
  • 12.4. Rare Disease

13. Biologics Contract Manufacturing Market, by End User

  • 13.1. Biotechnology Company
  • 13.2. Contract Service Provider
  • 13.3. Pharmaceutical Company
  • 13.4. Research Institute

14. Biologics Contract Manufacturing Market, by Manufacturing Model

  • 14.1. Dedicated Facility
  • 14.2. Fee For Service
  • 14.3. Multiproduct Facility
  • 14.4. Virtual Manufacturing

15. Biologics Contract Manufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Biologics Contract Manufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Biologics Contract Manufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Lonza Group Ltd.
    • 18.3.2. Samsung Biologics Co., Ltd.
    • 18.3.3. Catalent, Inc.
    • 18.3.4. Wuxi Biologics (Cayman) Inc.
    • 18.3.5. Thermo Fisher Scientific Inc.
    • 18.3.6. Boehringer Ingelheim International GmbH
    • 18.3.7. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
    • 18.3.8. AGC Biologics Inc.
    • 18.3.9. Recipharm AB
    • 18.3.10. KBI Biopharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFOR